PE20191646A1 - Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos - Google Patents

Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos

Info

Publication number
PE20191646A1
PE20191646A1 PE2019001773A PE2019001773A PE20191646A1 PE 20191646 A1 PE20191646 A1 PE 20191646A1 PE 2019001773 A PE2019001773 A PE 2019001773A PE 2019001773 A PE2019001773 A PE 2019001773A PE 20191646 A1 PE20191646 A1 PE 20191646A1
Authority
PE
Peru
Prior art keywords
6alkyl
compounds
alicyclics
derivatives
pharmacologically active
Prior art date
Application number
PE2019001773A
Other languages
English (en)
Spanish (es)
Inventor
Istvan Borza
Zsuzsa Hadady
Janos Eles
Viktor Roman
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PE20191646A1 publication Critical patent/PE20191646A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2019001773A 2017-03-13 2018-03-12 Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos PE20191646A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
PCT/IB2018/051599 WO2018167630A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
PE20191646A1 true PE20191646A1 (es) 2019-11-07

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001773A PE20191646A1 (es) 2017-03-13 2018-03-12 Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos

Country Status (32)

Country Link
US (1) US11026946B2 (cg-RX-API-DMAC7.html)
EP (1) EP3596080B1 (cg-RX-API-DMAC7.html)
JP (1) JP7153662B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190127779A (cg-RX-API-DMAC7.html)
CN (1) CN110431142A (cg-RX-API-DMAC7.html)
AR (1) AR111176A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018235266B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018843A2 (cg-RX-API-DMAC7.html)
CA (1) CA3056185A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002601A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019010120A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124708T1 (cg-RX-API-DMAC7.html)
DK (1) DK3596080T3 (cg-RX-API-DMAC7.html)
EA (1) EA038756B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19072975A (cg-RX-API-DMAC7.html)
ES (1) ES2893824T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20217256B (cg-RX-API-DMAC7.html)
HR (1) HRP20211850T1 (cg-RX-API-DMAC7.html)
HU (2) HU231058B1 (cg-RX-API-DMAC7.html)
IL (1) IL268923A (cg-RX-API-DMAC7.html)
LT (1) LT3596080T (cg-RX-API-DMAC7.html)
MX (1) MX2019011000A (cg-RX-API-DMAC7.html)
MY (1) MY195262A (cg-RX-API-DMAC7.html)
PE (1) PE20191646A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501968A1 (cg-RX-API-DMAC7.html)
PL (1) PL3596080T3 (cg-RX-API-DMAC7.html)
PT (1) PT3596080T (cg-RX-API-DMAC7.html)
RS (1) RS62533B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201907864YA (cg-RX-API-DMAC7.html)
SI (1) SI3596080T1 (cg-RX-API-DMAC7.html)
UA (1) UA124783C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018167630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241558T1 (hr) 2017-03-13 2025-03-28 Lundbeck La Jolla Research Center, Inc. Dvojni inhibitori magl i faah
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
JP2023520647A (ja) 2020-03-26 2023-05-18 リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体
CN120590392A (zh) 2020-08-05 2025-09-05 吉瑞工厂 药理学活性的杂环取代的吡唑并[1,5-a]嘧啶衍生物
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN115872095A (zh) * 2022-11-28 2023-03-31 南通三鑫车灯配件有限公司 一种汽车车灯反光罩的生产线流转装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557719A1 (en) 2004-03-02 2005-10-13 F. Hoffmann-La Roche Ag 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR100753017B1 (ko) 2006-05-25 2007-08-30 한국화학연구원 7-(3,4-디알콕시페닐)-피라졸로[1,5-a]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
EP3286192A1 (en) 2015-04-20 2018-02-28 AbbVie Deutschland GmbH & Co KG Substituted pyrazolopyrimidines and method of use
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Also Published As

Publication number Publication date
HUP1700108A2 (en) 2018-09-28
WO2018167630A1 (en) 2018-09-20
US11026946B2 (en) 2021-06-08
CY1124708T1 (el) 2022-07-22
RS62533B1 (sr) 2021-11-30
HUE056562T2 (hu) 2022-02-28
MY195262A (en) 2023-01-11
CO2019010120A2 (es) 2019-10-09
CA3056185A1 (en) 2018-09-20
EA038756B1 (ru) 2021-10-14
AR111176A1 (es) 2019-06-12
PH12019501968A1 (en) 2020-06-29
PT3596080T (pt) 2021-10-22
UA124783C2 (uk) 2021-11-17
AU2018235266A1 (en) 2019-10-17
SI3596080T1 (sl) 2022-01-31
HU231058B1 (hu) 2020-04-28
EA201992127A1 (ru) 2020-02-06
CL2019002601A1 (es) 2020-01-24
US20200129515A1 (en) 2020-04-30
KR20190127779A (ko) 2019-11-13
HRP20211850T1 (hr) 2022-03-04
LT3596080T (lt) 2021-11-25
EP3596080B1 (en) 2021-09-01
MX2019011000A (es) 2019-10-17
EP3596080A1 (en) 2020-01-22
BR112019018843A2 (pt) 2020-04-14
ES2893824T3 (es) 2022-02-10
PL3596080T3 (pl) 2022-01-31
JP7153662B2 (ja) 2022-10-14
DK3596080T3 (da) 2021-11-15
SG11201907864YA (en) 2019-09-27
AU2018235266B2 (en) 2021-09-30
IL268923A (en) 2019-10-31
GEP20217256B (en) 2021-05-25
JP2020510041A (ja) 2020-04-02
ECSP19072975A (es) 2019-11-30
CN110431142A (zh) 2019-11-08

Similar Documents

Publication Publication Date Title
PE20191646A1 (es) Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos
UY39723A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
DOP2023000016A (es) Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
ECSP21013035A (es) Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
AU2017268006A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
CL2020003197A1 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
CL2023000352A1 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
EA202190246A1 (ru) Производные тиадиазина
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
CO2019002616A2 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
MX2024008372A (es) Compuestos organicos deuterados y usos de los mismos
DOP2023000205A (es) Nuevos moduladores de nr2b alostéricos negativos de ciclopenta[c]pirrol
AR057300A1 (es) Estirilsulfonamidas, su obtencion y uso como agentes farmaceuticos
DOP2020000234A (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2
EA202192092A3 (ru) Тетрагидро-пиридо[3,4-b]индоловые модуляторы эстрогеновых рецепторов и их применение